Pharmaceutical care – impact on quality of life in patients with type 2 diabetes: a review

References

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 87(1):4–14.
   PubMed Web of Science ®Google Scholar
• World Health Assembly. Global strategy on diet, physical activity and health. In: Fifty-seventh World Health Assembly Geneva, May 17–22, 2004. Resolutions and Decisions, Annexes. Geneva: World Health Organization; 2004.
   Google Scholar
• Diabetes: fact sheet N°312 [webpage on the Internet]. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed November 21, 2012.
   Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405–12.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
   PubMed Web of Science ®Google Scholar
• Proudfoot J, Infante F, Holton C, et al. Organisational capacity and chronic disease care: an Australian general practice perspective. Aust Fam Physician. 2007;36(4):286–288.
   Google Scholar
• Harris M. Challenges in diabetes management. Aust Fam Physician. 2008;37(9):716–720.
   Google Scholar
• Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register1996–2003. Diabet Med. 2005;22(10):1420–1426.
   Web of Science ®Google Scholar
• Janus ED, Tideman PA, Dunbar JA, et al. Dyslipidaemia in rural Australia: prevalence, awareness, and adherence to treatment guidelines in the Greater Green Triangle Risk Factor Study. Med J Aust. 2010;192(3):127–132.
   Web of Science ®Google Scholar
• Krass I, Hebing R, Mitchell B, et al. Diabetes management in an Australian primary care population. J Clin Pharm Ther. 2011;36(6): 664–672.
   Web of Science ®Google Scholar
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533–543.
   PubMedGoogle Scholar
• Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41(10):1569–1582.
   Web of Science ®Google Scholar
• Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–436.
   PubMed Web of Science ®Google Scholar
• Evans CD, Watson E, Eurich DT, et al. Diabetes and cardiovascular disease interventions by community pharmacists: a systematic review. Ann Pharmacother. 2011;45(5):615–628.
   Web of Science ®Google Scholar
• Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15(6):1121–1132.
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205–218.
   PubMed Web of Science ®Google Scholar
• Rubin RR. Diabetes and quality of life. Diabetes Spectr. 2000;13(1): 21–23.
   Google Scholar
• What quality of life? The WHOQOL Group. World Health Organization Quality of Life Assessment. World Health Forum. 1996;17(4): 354–356.
   Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622–629.
   PubMed Web of Science ®Google Scholar
• Bhatt JK, Thomas S, Nanjan MJ. Health outcome measures for diabetes mellitus: a review. Appl Res Qual Life. 2012;7:413–443.
   Web of Science ®Google Scholar
• El Achhab Y, Nejjari C, Chikri M, Lyoussi B. Disease-specific health- related quality of life instruments among adults diabetic: a systematic review. Diabetes Res Clin Pract. 2008;80(2):171–184.
   PubMed Web of Science ®Google Scholar
• Speight J, Reaney MD, Barnard KD. Not all roads lead to Rome–a review of quality of life measurement in adults with diabetes. Diabet Med. 2009;26(4):315–327.
   Web of Science ®Google Scholar
• The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). Diabetes Care. 1988;11(9):725–732.
   PubMed Web of Science ®Google Scholar
• Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res. 1999;8(1–2):79–91.
   PubMed Web of Science ®Google Scholar
• The World Health Organization Quality of Life Assessment (WHO- QOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–1585.
   Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
   PubMed Web of Science ®Google Scholar
• Contopoulos-Ioannidis DG, Karvouni A, Kouri I, Ioannidis JPA. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ. 2009;338:a3006.
   PubMed Web of Science ®Google Scholar
• Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res. 1999;8(1–2):9–16.
   PubMed Web of Science ®Google Scholar
• van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between Euro Qol (EQ-5D) and WHOQoL. Qual Life Res. 2005;14(2):441–451.
   PubMed Web of Science ®Google Scholar
• Kheir NM, van Mil JW, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care. Targeting an outcome that matters. Pharm World Sci. 2004;26(3):125–128.
   Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.
   PubMed Web of Science ®Google Scholar
• Armour CL, Taylor SJ, Hourihan F, Smith C, Krass I. Implementation and evaluation of Australian pharmacists’ diabetes care services. J Am Pharm Assoc (2003). 2004;44(4):455–66.
   Google Scholar
• Clifford RM, Batty KT, Davis TME, et al. A randomised controlled trial of a pharmaceutical care programme for high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract. 2002;10(2):85–89.
   Google Scholar
• Krass I, Armour CL, Mitchell B, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med. 2007;24(6):677–683.
   PubMed Web of Science ®Google Scholar
• Krass I, Mitchell B, Song YJ, et al. Diabetes Medication Assistance Service Stage 1: impact and sustainability of glycaemic and lipids control in patients with type 2 diabetes. Diabet Med. 2011;28(8):987–993.
   Web of Science ®Google Scholar
• Balisa-Rocha BJ, Guimaraues VG, Mesquita AR, Aguiar PM, Krass I, Pereira de Lyra D Jr. Enhancing health care for type 2 diabetes in Northen Brazil: a pilot study of pharmaceutical care in community pharmacy. Afr J Pharm Pharmacol. 2012;6(35):2584–2591.
   Google Scholar
• Correr CJ, Pontarolo R, Souza R, Venson R, Melchiors AC, Wiens A. Effect of a pharmaceutical care program on quality of life and satisfaction with pharmacy services in patients with type 2 diabetes mellitus. Braz J Pharm Sci. 2009;45(4):809–817.
   Web of Science ®Google Scholar
• Guirguis LM, Johnson JA, Farris KB, Tsuyuki RT, Toth EL. A pilot study to evaluate the impact of pharmacists as certified diabetes educators on the clinical and humanistic outcomes of people with diabetes. Can J Diabetes Care. 2001;25(4):266–276.
   Google Scholar
• Arun KP, Murugan R, Kanna MR, Rajalakshmi S, Kalaiselvi R, Komathi V. The impact of pharmaceutical care on the clinical outcome of diabetes mellitus among a rural patient population. Int J Diabetes Dev Ctries. 2008;28(1):15–18.
   Web of Science ®Google Scholar
• Sriram S, Chack LE, Ramasamy R, Ghasemi A, Ravi TK, Sabzghabaee AM. Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci. 2011;16(Suppl 1): S412–S418.
   Google Scholar
• Abduelkarem A, Sackville M. Changes of some health indicators in patients with type 2 diabetes: a prospective study in three community pharmacies in Sharjah, United Arab Emirates. Libyan J Med. 2009;4(1):31–36.
   Web of Science ®Google Scholar
• Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67(5):547–557.
   PubMed Web of Science ®Google Scholar
• Ali M, Schifano F, Robinson P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: a randomized controlled study. Diabet Med. 2012;29(9): e326–e333.
   PubMed Web of Science ®Google Scholar
• Baran RW, Crumlish K, Patterson H, et al. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling. Am J Health Syst Pharm. 1999;56(15):1535–1539.
   Web of Science ®Google Scholar
• Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):149–159.
   Google Scholar
• Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30(3):238–243.
   PubMed Web of Science ®Google Scholar
• Johnson CL, Nicholas A, Divine H, Perrier DG, Blumenschein K, Steinke DT. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. J Am Pharm Assoc (2003). 2008;48(6): 722–730.
   Web of Science ®Google Scholar
• Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63(21):2116–2122.
   PubMed Web of Science ®Google Scholar
• Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2): 173–184.
   PubMedGoogle Scholar
• Taylor SJ, Milanova T, Hourihan F, Krass I, Coleman C, Armour CL. A cost-effectiveness analysis of a community pharmacist-initiated disease state management service for type 2 diabetes mellitus. Int J Pharm Pract. 2001;13(1):33–40.
   Google Scholar
• Krass I, Armour CL, Clarke P, et al. Pharmacy Diabetes Care Program. Available from: http://www.guild.org.au/iwov-resources/documents/The_Guild/PDFs/CPA%20and%20Programs/3CPA%20 General/2002–518/2002–518_fr.pdf. Accessed December 16,2012.
   Google Scholar
• Vermeire E, Wens J, Van Royen P, BiotY, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;2:CD003638.
   Google Scholar
• Egginton JS, Ridgeway JL, Shah ND, et al. Care management for type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Serv Res. 2012;12:72.
   Web of Science ®Google Scholar
• Health Quality Ontario. Community-based care for the management of type 2 diabetes: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(23):1–40.
   Google Scholar
• Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11(4):253–260.
   PubMed Web of Science ®Google Scholar
• Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280(17):1490–1496.
   Web of Science ®Google Scholar
• Anderson RT, Narayan KM, Feeney P, et al. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care. 2011;34(4):807–812.
   Web of Science ®Google Scholar
• Delamater AM, Jacobson AM, Anderson B, et al. Psychosocial therapies in diabetes: report of the Psychosocial Therapies Working Group. Diabetes Care. 2001;24(7):1286–1292.
   Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14(1):18–24.
   Web of Science ®Google Scholar
• Burroughs TE, Desikan R, Waterman BM, Gilin D, McGill J. Development and validation of the diabetes quality of life brief clinical inventory. Diabetes Spectr. 2004;17:41–49.
   Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;10:135–140.
   Google Scholar
• Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicienes Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10(3):135–140.
   PubMedGoogle Scholar
• Bradley C. The 12-Item Well-Being Questionnaire: origins, current stage of development, and availability. Diabetes Care. 2000;23(6):875.
   Web of Science ®Google Scholar
• Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Breif Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. Jun 1999;37(2):113–124.
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Care Rsearch Group, University of Granada (Spain). Pharmacotherapy follow-up: the Dader method (3rd revision: 2005). Pharmacy Practice. 2006;4(1):44–53.
   Google Scholar
• Correr CJ, Pontarolo R, Melchiors AC, Rossignoli P, Fernandez-Llimos F, Radominski RB. [Translation to portuguese and validation of the Diabetes Quality Of Life Measure (DQOL-Brazil;)]. Arq Bras Endocrinol Metabol. 2008;52(3):515–522.
   Google Scholar
• Jenkinson C, Layte R. Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Policy. 1997;2(1):14–18.
   PubMedGoogle Scholar
• MacKeigan LD, Larson LN. Development and validation of an instrument to measure patient satisfaction with pharmacy services. Med Care. 1989;27(5):522–536.
   Web of Science ®Google Scholar
• Johson JA. Coons SJ, Hays RD, Pickard AS. Health status and satisfaction with pharmacy services. Am J Manag Care. Feb 1999;5(2):163–170.
   Web of Science ®Google Scholar
• Health status questionnaire 2.0 user guide. Bloomington, MN: Health Outcome Institute; 1993.
   Google Scholar
• The EuroQol Group. EuroQol–A new facility for the measurement of health related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes. 2007;5:57.
   PubMed Web of Science ®Google Scholar
• Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000;23(7):943–950.
   PubMed Web of Science ®Google Scholar
• Glasgow RE, Barrera M, Mckay HG, Boles SM. Social support, self-management, and quality of life among participants in an internet-based diabetes support program. Cyber Psychol and Behav. 1999;2:271–281.
   PubMedGoogle Scholar
• Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26(7):724–735.
   PubMed Web of Science ®Google Scholar